33 - References

References

834 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 10 Cognitive symptoms Cognitive disturbances may emerge many years before motor disturbances.7 The progression of cognitive decline is gradual25 and dementia is inevitable in late stages. Although a wide variety of agents have been studied,2,11 none has become established treatment and the benefit of most remains unclear.26 There is insufficient evidence to support the use of acetylcholinesterase inhibitors27 and no evidence to support any other medications to treat dementia in HD.11,28 References

1. Medina A, et al. Prevalence and incidence of Huntington’s disease: an updated systematic review and meta-­analysis. Mov Disord 2022; 37:2327–2335.
2. Ferreira JJ, et al. An MDS evidence-­based review on treatments for Huntington’s disease. Mov Disord 2022; 37:25–35.
3. Mestre T, et al. Therapeutic interventions for disease progression in Huntington’s disease. Cochrane Database Syst Rev 2009; 2009:CD006455.
4. Van de Roovaart HJ, et al. Huntington’s disease drug development: a phase 3 pipeline analysis. Pharmaceuticals (Basel) 2023; 16:1513.
5. Killoran A, et al. Current therapeutic options for Huntington’s disease: good clinical practice versus evidence-­based approaches? Mov Disord 2014; 29:1404–1413.
6. Anderson KE, et  al. Clinical management of neuropsychiatric symptoms of Huntington disease: expert-­based consensus guidelines on ­agitation, anxiety, apathy, psychosis and sleep disorders. J Huntingtons Dis 2018; 7:355–366.
7. McColgan P, et al. Huntington’s disease: a clinical review. Eur J Neurol 2018; 25:24–34.
8. Bachoud-­Lévi AC, et al. International guidelines for the treatment of Huntington’s disease. Front Neurol 2019; 10:710.
9. Furr Stimming E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-­HD): a phase 3, randomised, double-­blind, placebo-­controlled trial. Lancet Neurol 2023; 22:494–504.
10. Unti E, et al. Antipsychotic drugs in Huntington’s disease. Expert Rev Neurother 2017; 17:227–237.
11. Saft C, et al. Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society). Neurol Res Pract 2023; 5:61.
12. Javelot H, et al. Benefit of long-­acting paliperidone in Huntington’s disease: a case report. Int Clin Psychopharmacol 2021; 36:101–103.
13. Eddy CM, et al. Changes in mental state and behaviour in Huntington’s disease. Lancet Psychiatry 2016; 3:1079–1086.
14. Desamericq G, et al. Guidelines for clinical pharmacological practices in Huntington’s disease. Rev Neurol (Paris) 2016; 172:423–432.
15. Jellinger KA. The pathobiology of depression in Huntington’s disease: an unresolved puzzle. J Neural Transm 2024; doi: 10.1007/ s00702-­024-­02750-­w.
16. Moulton CD, et al. Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease. Mov Disord 2014; 29:1556–1561.
17. Zadegan SA, et al. Treatment of depression in Huntington’s disease: a systematic review. J Neuropsychiatry Clin Neurosci 2024; doi: 10.1176/ appi.neuropsych.20230120.
18. van Duijn E. Medical treatment of behavioral manifestations of Huntington disease. Handb Clin Neurol 2017; 144:129–139.
19. McLauchlan DJ, et al. Different depression: motivational anhedonia governs antidepressant efficacy in Huntington’s disease. Brain Commun 2022; 4:fcac278.
20. Yahya A, et al. Electroconvulsive therapy in Huntington’s disease. Prog Neurol Psychiatry 2021; 25:33–38.
21. Oosterloo M, et al. Obsessive-­compulsive and perseverative behaviors in Huntington’s disease. J Huntingtons Dis 2019; 8:1–7.
22. Karagas NE, et al. Irritability in Huntington’s disease. J Huntingtons Dis 2020; 9:107–113.
23. Fisher CA, et al. Aggression in Huntington’s disease: a systematic review of rates of aggression and treatment methods. J Huntingtons Dis 2014; 3:319–332.
24. Connolly A, et al. Meta-­analysis and systematic review of vesicular monoamine transporter (VMAT-­2) inhibitors in schizophrenia and psychosis. Psychopharmacology (Berl) 2024; 241:225–241.
25. Ross CA, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014; 10:204–216.
26. Van der Vaart T, et al. Treatment of cognitive deficits in genetic disorders: a systematic review of clinical trials of diet and drug treatments. JAMA Neurol 2015; 72:1052–1060.
27. Li Y, et  al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev 2015; 3:CD009444.
28. O’Brien JT, et  al. Clinical practice with anti-­dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2017; 31:147–168.